Compare Home Depot Inc (HD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Novo Nordisk A/S — how do they compare? Home Depot Inc trades at $291.02 (market cap $294.79B), while Novo Nordisk A/S trades at $38.41 (market cap $165.31B). The key difference: Home Depot Inc is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Novo Nordisk A/S for 116 Days on average.
| HD | NVO | |
|---|---|---|
Market Cap | $294.79B | $165.31B |
Volume | 8,693,917 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $63.98 |
52-Week Low | $281.15 | $35.29 |
Typical Hold Time | 139 Days | 116 Days |
Enterprise Value | $355.27B | $179.56B |
Dividend Yield | 3.15% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $285.77, down 0.32% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats in recent quarters with Q2 2026 EPS of $4.92 exceeding expectations. Revenue reached $159.51B in 2025, though profit margins have declined from 10.87% in 2022 to 9.28% currently. Institutional activity shows mixed positioning with some funds increasing while others reducing holdings.
The stock presents a compelling value opportunity with a consensus price target of $379.93 representing 33% upside potential. However, weakening profit margins, rising mortgage rates impacting housing demand, and bearish technical indicators create near-term headwinds. Long-term prospects remain supported by professional segment growth and housing market tailwinds.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
